Oric Pharmaceuticals

ORIC

Market cap $1.31B

The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the “Grant Date”), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will be participating in the following investor conferences in February:

ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity raise, secures operations and Phase 3 trial funding into the second half of 2028. Rinzimetostat and enozertinib have shown promising efficacy and safety in early trials, with both candidates entering registrational Phase 3 studies by 2026.

ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:45 a.m. PT.

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript